These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 17102040)

  • 61. [Contrast agents in MRT. Substance, effects, pharmacology and validity].
    Reimer P; Vosshenrich R
    Radiologe; 2004 Mar; 44(3):273-83. PubMed ID: 15287365
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Magnetic resonance imaging. Liver-specific contrast agents.
    Ji H; Ros PR
    Clin Liver Dis; 2002 Feb; 6(1):73-90. PubMed ID: 11933597
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Magnetic resonance of the liver with hepato-specific contrast: initial clinical experience in Brazil.
    Bittencourt LK; Hausmann D; Gasparetto EL; Domingues RC
    Rev Col Bras Cir; 2013; 40(3):237-40. PubMed ID: 23912373
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Gadolinium-based contrast agents in pediatric magnetic resonance imaging.
    Gale EM; Caravan P; Rao AG; McDonald RJ; Winfeld M; Fleck RJ; Gee MS
    Pediatr Radiol; 2017 May; 47(5):507-521. PubMed ID: 28409250
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Hepatocyte-specific contrast media: not so simple.
    Trout AT; Towbin AJ; Smith EA; Gupta A; Dillman JR
    Pediatr Radiol; 2018 Aug; 48(9):1245-1255. PubMed ID: 30078050
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Nodular regenerative hyperplasia of the liver and portal thrombosis.
    Onur MR; Poyraz AK; Kocakoç E
    JBR-BTR; 2012; 95(3):162-3. PubMed ID: 22880521
    [No Abstract]   [Full Text] [Related]  

  • 67. [Out of phase magnetic resonance imaging and liver applications].
    Chave G; Milot L; Pilleul F
    J Radiol; 2005 Sep; 86(9 Pt 1):993-7. PubMed ID: 16224338
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Principles of contrast enhancement in the evaluation of brain diseases: an overview.
    Runge VM; Muroff LR; Wells JW
    J Magn Reson Imaging; 1997; 7(1):5-13. PubMed ID: 9039588
    [TBL] [Abstract][Full Text] [Related]  

  • 69. MRI of the liver--how to do it.
    Vasanawala SS
    Pediatr Radiol; 2010 Apr; 40(4):431-7. PubMed ID: 20225098
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Chelates of gadolinium and dysprosium as contrast agents for MR imaging.
    Rocklage SM; Watson AD
    J Magn Reson Imaging; 1993; 3(1):167-78. PubMed ID: 8428084
    [No Abstract]   [Full Text] [Related]  

  • 71. Noninvasive liver imaging: new techniques and practical strategies.
    Longmaid HE; Dupuy DE; Kane RA; Finn JP; Costello P
    Semin Ultrasound CT MR; 1992 Oct; 13(5):377-98. PubMed ID: 1419142
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Currently used non-specific extracellular MR contrast media.
    Bellin MF; Vasile M; Morel-Precetti S
    Eur Radiol; 2003 Dec; 13(12):2688-98. PubMed ID: 12819914
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [Magnetic resonance imaging in orthopaedic medicine].
    Straub R; Mack MG; Jacobi V; Proschek D; Vogl TJ
    Orthopade; 2006 Jun; 35(6):626-31. PubMed ID: 16568256
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Hepatocyte-specific contrast agent-enhanced magnetic resonance cholangiography: perioperative evaluation of the biliary tree.
    Zattar-Ramos LC; Bezerra ROF; Siqueira LTB; Menezes MR; Leite CDC; Cerri GG
    Radiol Bras; 2017; 50(6):389-394. PubMed ID: 29307930
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Altered Nulling of Myocardium and Blood Pool.
    Tailor TD; Mammarappallil JG; Christensen JD
    J Thorac Imaging; 2017 Jan; 32(1):W1-W2. PubMed ID: 27879492
    [No Abstract]   [Full Text] [Related]  

  • 76. Introduction to the gadolinium class.
    Brasch RC
    J Comput Assist Tomogr; 1993; 17 Suppl 1():S14-8. PubMed ID: 8486826
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Advances in functional and molecular MRI technologies in chronic liver diseases.
    Zhou IY; Catalano OA; Caravan P
    J Hepatol; 2020 Nov; 73(5):1241-1254. PubMed ID: 32585160
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Targeted MRI contrast agents for pediatric hepatobiliary disease.
    Courtier JL; Perito ER; Rhee S; Tsai P; Heyman MB; MacKenzie JD
    J Pediatr Gastroenterol Nutr; 2012 Apr; 54(4):454-62. PubMed ID: 22193178
    [TBL] [Abstract][Full Text] [Related]  

  • 79. MR imaging of diffuse liver disease.
    Danet IM; Semelka RC; Braga L
    Radiol Clin North Am; 2003 Jan; 41(1):67-87. PubMed ID: 12630686
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Role of Contrast in MR Imaging.
    Chandra T; Mohan S
    Top Magn Reson Imaging; 2016 Aug; 25(4):151-6. PubMed ID: 27367311
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.